United Kingdom (UK)
Recombinant monoclonal antibody to CTLA-4. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody NB25B-17.
UniProt Accession Number of Target Protein: P16410
Alternative Name(s) of Target: Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; CD152
Immunogen: The original antibody was generated by immunizing alpaca with human CTLA-4, followed by antibody library construction and phage display-based selection.
Specificity: The antibody is specific for CTLA-4. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses.
Application Notes: The binding affinity of humanized VHH-Fc chimeric antibody to human CTLA-4 expressed in CHO cells was shown by FACS experiments. The blocking activity of the humanized VHH-Fc chimeric antibody to the binding of CTLA-4 to CD80 or CD86 was shown using FACS. The antitumor activity of the humanized antibody was demonstrated in vivo in animal models. Specifically, a tumor animal model was established by inoculating mice with human breast cancer cells MDA-MB-231 (ATCC) to induce breast cancer. Mice were grouped and administered with the humanized version of the antibody, and tumor volume in tumor-bearing animals was measured periodically in size. Results showed that the humanized version of the antibody was able to significantly reduce tumor volume in tumor-bearing mice (CN113121689).
Antibody first published in: PMID: